Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

NCT05357573 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor-Induced Osteomalacia (TIO)

Interventions

DRUG: KRN23

Sponsor

Kyowa Kirin Co., Ltd.